SLU-PP-332 Ireland | Buy SLU-PP-332 | Research-Grade ≥99% Purity

SLU-PP-332 is a potent synthetic agonist of the ERR (oestrogen-related receptor) family of nuclear receptors — one of the most significant emerging compounds in exercise mimetic, mitochondrial biology, and metabolic research — available to buy in Ireland with fast dispatch and full batch documentation included.

SLU-PP-332 activates ERRα, ERRβ, and ERRγ simultaneously — the three nuclear receptors that act as master regulators of mitochondrial biogenesis, oxidative metabolism, and energy expenditure — producing gene expression changes in skeletal muscle, heart, and metabolic tissues that closely parallel the adaptations induced by endurance exercise training. Researchers and institutions across Ireland can source verified, research-grade SLU-PP-332 directly from our Irish supply, with domestic-speed dispatch and complete batch documentation.

✅ ≥99% Purity — HPLC & Mass Spectrometry Verified

✅ Batch-Specific Certificate of Analysis (CoA) Included

✅ Sterile Lyophilised Powder | GMP Manufactured

✅ Fast Dispatch to Ireland | Peptides Ireland Stock

What Is SLU-PP-332?

SLU-PP-332 is a small molecule synthetic compound developed at Saint Louis University as a pan-ERR agonist — meaning it activates all three members of the oestrogen-related receptor family: ERRα, ERRβ, and ERRγ. Despite their name, oestrogen-related receptors do not bind oestrogen — they are constitutively active nuclear receptors that regulate the transcription of genes involved in mitochondrial biogenesis, fatty acid oxidation, oxidative phosphorylation, and cellular energy metabolism, particularly in tissues with high energy demands such as skeletal muscle, cardiac muscle, and brown adipose tissue.

ERRα, ERRβ, and ERRγ function as central coordinators of the transcriptional response to exercise and energy stress — activating many of the same gene expression programmes that are induced by endurance training, including genes encoding mitochondrial proteins, oxidative enzymes, and metabolic regulators. Their activity closely overlaps with PGC-1α — the well-known exercise-responsive transcriptional coactivator — with ERRs functioning as direct downstream effectors of PGC-1α-driven metabolic gene programmes.

SLU-PP-332 was specifically designed to bind and activate all three ERR subtypes simultaneously — an approach that distinguishes it from earlier ERR-selective compounds and makes it a uniquely comprehensive tool for studying pan-ERR activation and the full scope of ERR-driven transcriptional reprogramming in metabolic and exercise biology research.

What Does SLU-PP-332 Do in Research?

In controlled laboratory and pre-clinical settings, SLU-PP-332 is studied across a wide range of metabolic, exercise biology, mitochondrial, and cardiovascular research applications:

Pan-ERR Agonism and Nuclear Receptor Biology Research — SLU-PP-332’s defining research property is its simultaneous activation of ERRα, ERRβ, and ERRγ — making it the primary research tool for studying the combined transcriptional output of pan-ERR activation and how the three receptor subtypes cooperate to drive mitochondrial and metabolic gene programmes. Studies have examined receptor binding profiles, transcriptional activation potency, and the relative contributions of each ERR subtype to downstream biological effects.

Exercise Mimetic Research — SLU-PP-332 is one of the most potent and mechanistically relevant exercise mimetic compounds currently available for research. Studies have examined how SLU-PP-332 treatment in skeletal muscle reproduces the gene expression signature of endurance exercise training — including upregulation of mitochondrial biogenesis genes, oxidative phosphorylation components, and fatty acid oxidation enzymes — making it a key tool for dissecting the molecular basis of exercise adaptation independent of the mechanical and neural signals of actual physical activity.

Mitochondrial Biogenesis Research — ERR activation is one of the most direct pharmacological routes to stimulating mitochondrial biogenesis — the process by which cells increase their mitochondrial content and oxidative capacity. Studies have used SLU-PP-332 to examine mitochondrial biogenesis markers including PGC-1α, TFAM, citrate synthase activity, and mitochondrial DNA copy number in skeletal muscle and other metabolic tissues — establishing it as a leading research tool for mitochondrial biology.

Obesity and Metabolic Disease Research — Pre-clinical studies have examined SLU-PP-332’s effects on body weight, fat mass, and metabolic parameters in diet-induced obesity models — with research documenting significant reductions in fat mass, improvements in glucose metabolism, and enhanced energy expenditure following SLU-PP-332 treatment through ERR-driven increases in oxidative metabolism and mitochondrial activity.

Skeletal Muscle Oxidative Capacity Research — Studies have examined how SLU-PP-332 affects skeletal muscle fibre type composition, oxidative enzyme activity, and mitochondrial density — with research documenting shifts towards more oxidative muscle phenotypes in treated pre-clinical models, paralleling the muscle adaptations produced by endurance exercise training.

Cardiac Biology and Heart Failure Research — The heart is one of the most ERR-rich tissues in the body, with ERRα and ERRγ playing critical roles in maintaining cardiac energy metabolism. Studies have examined SLU-PP-332’s effects on cardiac function, mitochondrial metabolism, and heart failure biology in pre-clinical models — with research suggesting potential cardioprotective effects through restoration of ERR-driven oxidative metabolism in metabolically stressed cardiac tissue.

Fatty Acid Oxidation Research — ERRs are master regulators of fatty acid oxidation gene programmes, and SLU-PP-332 is used to study how pan-ERR activation affects lipid metabolism — including fatty acid uptake, beta-oxidation enzyme expression, and the shift from glucose to fatty acid utilisation in skeletal muscle and other metabolic tissues.

Energy Expenditure Research — Studies have examined SLU-PP-332’s effects on whole-body energy expenditure in pre-clinical models — with research using indirect calorimetry to document increased oxygen consumption and energy expenditure following treatment, consistent with ERR-driven increases in mitochondrial oxidative activity across metabolic tissues.

Ageing and Sarcopenia Research — Age-related decline in ERR activity and mitochondrial function contributes to sarcopenia — the loss of muscle mass and function with ageing. Research has examined whether SLU-PP-332 can restore ERR-driven mitochondrial gene programmes in aged muscle tissue — positioning it as a research tool for studying the interface between ERR biology, mitochondrial ageing, and age-related muscle decline.

PGC-1α Pathway Research — SLU-PP-332 is used as a research tool for studying the PGC-1α/ERR transcriptional axis — one of the most important regulatory pathways in exercise and metabolic biology. Studies examine how pan-ERR activation interacts with PGC-1α coactivation, how the two work together to drive mitochondrial gene programmes, and what SLU-PP-332 reveals about the downstream effector mechanisms of PGC-1α signalling.

What Do Studies Say About SLU-PP-332?

SLU-PP-332 has a compelling and rapidly growing pre-clinical research profile, with several high-profile studies establishing it as one of the most significant exercise mimetic compounds in current research:

Potent Pan-ERR Activation Confirmed — Biochemical and cell-based studies have confirmed that SLU-PP-332 is a potent agonist of ERRα, ERRβ, and ERRγ — with receptor binding and transcriptional activation assays documenting high-potency activation of all three subtypes at nanomolar to low micromolar concentrations, establishing it as the most comprehensive pan-ERR research tool currently available.

Exercise Gene Signature Reproduced in Skeletal Muscle — Studies have demonstrated that SLU-PP-332 treatment in skeletal muscle cells and pre-clinical models produces a gene expression profile that closely resembles the transcriptional signature of endurance exercise training — including upregulation of hundreds of genes related to mitochondrial biogenesis, oxidative phosphorylation, and fatty acid metabolism — providing strong evidence for its characterisation as a genuine exercise mimetic at the molecular level.

Significant Fat Mass Reduction in Pre-Clinical Obesity Models — Pre-clinical obesity studies have reported substantial reductions in body weight and fat mass in SLU-PP-332-treated animals on high-fat diets — with research documenting improved metabolic parameters including glucose tolerance and insulin sensitivity alongside the fat mass reductions, linked to ERR-driven increases in energy expenditure and oxidative metabolism.

Increased Running Endurance in Pre-Clinical Models — One of the most striking findings in the SLU-PP-332 research literature is the documentation of significantly increased running endurance in treated pre-clinical models — with studies reporting substantially greater exercise capacity in SLU-PP-332-treated animals compared to controls, consistent with ERR-driven improvements in skeletal muscle oxidative capacity and mitochondrial function.

Cardioprotective Effects in Pre-Clinical Models — Pre-clinical cardiac studies have reported protective effects of SLU-PP-332 in heart failure models — with research documenting preservation of cardiac function, improved cardiac energy metabolism, and reduced cardiac dysfunction in SLU-PP-332-treated animals compared to controls, supporting ERR activation as a potential research strategy for studying metabolic heart disease biology.

Enhanced Mitochondrial Content and Function — Studies have documented increases in mitochondrial biogenesis markers, citrate synthase activity, and mitochondrial density in skeletal muscle and cardiac tissue following SLU-PP-332 treatment — providing direct evidence that pan-ERR activation translates into functional increases in mitochondrial content and oxidative capacity in target tissues.

Renal Protection in Pre-Clinical Models — Emerging research has examined SLU-PP-332’s effects in pre-clinical kidney disease models — with studies suggesting ERR activation may support renal tubular cell metabolism and protect against kidney injury, reflecting the broad tissue relevance of ERR-driven mitochondrial biology beyond skeletal muscle and heart.

How Does SLU-PP-332 Compare to Other Exercise Mimetic Research Compounds?

Feature	SLU-PP-332	MOTS-c	GW501516 (Cardarine)	AICAR
Type	Pan-ERR nuclear receptor agonist	Mitochondria-derived peptide	PPARδ agonist	AMPK activator (AMP analogue)
Primary Target	ERRα / ERRβ / ERRγ	AMPK / mitochondrial stress signalling	PPARδ	AMPK
Mechanism	Nuclear receptor transcriptional activation	Mitochondrial stress peptide signalling	Fatty acid oxidation gene activation	Direct AMPK phosphorylation
Mitochondrial Biogenesis	Very high — direct ERR/PGC-1α axis	Moderate — AMPK-driven	Moderate	Moderate — AMPK-driven
Endurance / Performance Data	Yes — significant pre-clinical endurance increase	Limited direct performance data	Yes — pre-clinical endurance data	Yes — pre-clinical data
Cardiac Biology Relevance	Very high — ERR-rich cardiac tissue	Moderate	Low	Low
Key Research Distinction	Only pan-ERR agonist / most complete exercise transcriptome	Physiological mitochondrial signal	PPARδ-specific fat oxidation	Direct AMPK activation reference tool

SLU-PP-332 is the only compound that simultaneously activates all three ERR subtypes — giving it the most complete coverage of the ERR transcriptional network and the most comprehensive exercise mimetic gene expression profile of any single compound currently available for research.

Product Specifications

Parameter	Detail
Name	SLU-PP-332
Type	Small molecule pan-ERR agonist
Targets	ERRα, ERRβ, ERRγ
Primary Mechanism	Pan-ERR nuclear receptor activation / mitochondrial biogenesis / oxidative metabolism
Key Research Areas	Exercise mimetic / mitochondrial biology / metabolic disease / cardiac biology
Purity	≥99% HPLC & MS Verified
Form	Sterile Lyophilised Powder
Solubility	DMSO; dilute into aqueous buffer for working solutions
Storage (Powder)	-20°C, protect from light
Storage (Reconstituted)	-20°C, use promptly after thawing
Manufacturing	GMP Manufactured

Buy SLU-PP-332 in Ireland — What’s Included

Every order of SLU-PP-332 in Ireland includes:

✅ Batch-Specific Certificate of Analysis (CoA)

✅ HPLC Chromatogram

✅ Mass Spectrometry Confirmation

✅ Sterility & Endotoxin Testing Report

✅ Reconstitution Protocol

✅ Technical Research Support

Frequently Asked Questions

Can I buy SLU-PP-332 in Ireland? Yes — we supply research-grade SLU-PP-332 to researchers and institutions across Ireland with fast dispatch and full batch documentation. This compound is supplied strictly for laboratory research purposes only.

What is SLU-PP-332 and what makes it significant in research? SLU-PP-332 is a synthetic pan-ERR agonist — a compound that simultaneously activates all three oestrogen-related receptors (ERRα, ERRβ, ERRγ), which are master regulators of mitochondrial biogenesis and oxidative metabolism. Its significance lies in its ability to reproduce the molecular signature of endurance exercise training at the gene expression level — making it one of the most mechanistically complete and pharmacologically relevant exercise mimetic research compounds currently available.

What are ERRs and why are they important in metabolic research? Oestrogen-related receptors (ERRα, ERRβ, ERRγ) are nuclear receptors that regulate the transcription of hundreds of genes involved in mitochondrial function, fatty acid oxidation, oxidative phosphorylation, and energy metabolism — particularly in tissues with high energy demands like skeletal muscle and heart. Despite their name they do not bind oestrogen. They are major downstream effectors of PGC-1α — the master exercise-responsive transcriptional coactivator — and their combined activation by SLU-PP-332 produces a transcriptional output that closely mirrors the gene expression changes induced by endurance exercise training.

How does SLU-PP-332 differ from GW501516 (Cardarine) as an exercise mimetic? GW501516 activates PPARδ — a nuclear receptor that drives fatty acid oxidation and some exercise-related gene programmes. SLU-PP-332 activates ERRα, ERRβ, and ERRγ — a broader and more directly exercise-relevant set of nuclear receptors that regulate a wider transcriptional programme including mitochondrial biogenesis, oxidative phosphorylation, and the full scope of endurance adaptation biology. Research positions SLU-PP-332 as producing a more complete exercise transcriptome than PPARδ-selective compounds, though both remain important and complementary research tools for different aspects of exercise and metabolic biology.

Has SLU-PP-332 shown endurance and performance effects in research? Yes — pre-clinical studies have reported significantly increased running endurance in SLU-PP-332-treated animals compared to controls, consistent with ERR-driven improvements in skeletal muscle oxidative capacity and mitochondrial function. These endurance findings, alongside fat mass reduction and metabolic improvement data, represent some of the most discussed results in the SLU-PP-332 pre-clinical research literature.

What purity is recommended for SLU-PP-332 research? ≥99% purity is strongly recommended for ERR binding assays, transcriptional activation studies, mitochondrial biogenesis experiments, and in vivo pre-clinical models where compound quality directly affects receptor activation potency and reproducibility. All SLU-PP-332 Ireland stock is independently verified to ≥99%.

How do I reconstitute SLU-PP-332 for laboratory use? SLU-PP-332 is best initially dissolved in DMSO to prepare a concentrated stock solution, then diluted into aqueous buffer or cell culture media to working concentration — keep DMSO below 0.1% in final working solutions for cell-based assays to avoid solvent cytotoxicity. Store stock solutions at -20°C protected from light and avoid repeated freeze-thaw cycles to preserve compound stability and biological activity.

Research Disclaimer

SLU-PP-332 is supplied exclusively for legitimate scientific research purposes conducted within licensed laboratory environments. This product is not intended for human consumption, self-administration, or any therapeutic application. It must be handled by qualified researchers in compliance with applicable Irish and EU regulations and institutional ethics guidelines. By purchasing, you confirm that this compound will be used solely for approved in-vitro or pre-clinical research purposes.